70 likes | 291 Views
Trimonabant – tackling a modern epidemic . Jusni Saladdin Development Head, Metabolic Diseases. The Context. Obesity is a rapidly growing problem in the western world Nearly a quarter of the UK population is obese The cost to health authorities is huge
E N D
Trimonabant – tackling a modern epidemic Jusni Saladdin Development Head, Metabolic Diseases
The Context • Obesity is a rapidly growing problem in the western world • Nearly a quarter of the UK population is obese • The cost to health authorities is huge • Glazmerzer needs a product for this market
Mode of Action • Evidence came from cannabis smokers • Trimonabant targets receptors in the brain • Appetite is suppressed removing sensation of hunger • Needs to be taken with strict diet
Phase II Trials • Volunteers chosen were obese, or overweight. • Participants were placed on a strict diet, and received Trimonabant or a placebo. • The study was 'double blind‘. • Patients on high dose of Trimonabant lost more weight than those on just placebo. • Significant weight loss from the abdomen. • Evidence of minor side effects
Phase III Trials • Relatively inexpensive - $400 million • Easy to recruit for and easy to compare • Risks • Phase II was short term. Concern about longer term effect on nervous system • Competitor’s drug shows serious side effects • Might not work long-term or on all patients
Market Considerations • Need a product for this huge market • Trimonabant – a likely blockbuster • Manufacture is straightforward • Welcomed by Health Care Authorities – the cost of treating obesity is huge • Need to be first to Regulators